AKARI THERAPEUTICS
Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression. Akari's lead drug candidate, Nomacopan (formerly known as Coversin), is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity. Nomacopan is currently being clinically evaluated in four areas: bullous pemphigoid (BP), thrombotic microangiopathy (TMA), as well as programs in the eye and lung.
AKARI THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
2004-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.akaritx.com
Total Employee:
11+
Status:
Active
Contact:
646.350.0702
Email Addresses:
[email protected]
Total Funding:
114.25 M USD
Technology used in webpage:
CrUX Dataset Person Schema CrUX Top 50m Gravatar Profiles Visa Java EE Mobile Optimized Drupal Adobe Dynamic Tag Management Drupal 10
Similar Organizations
Ansun BioPharma
Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of host-directed anti-viral.
CureVac
CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA.
Dare Bioscience
Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Keros Therapeutics
Keros is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of novel treatments.
Point Biopharma
Point Biopharma focused on the development and commercialization of radioligand therapies for the treatment of cancer.
Vivoryon Therapeutics
Vivoryon is a clinical stage company focused on bringing first-in-class therapies to patients suffering from age-related diseases.
Regulus Therapeutics
Regulus Therapeutics is a clinical stage biopharmaceutical company focused on the development and discovery of microRNA therapeutics.
Stealth BioTherapeutics
Stealth BioTherapeutics is a clinical-stage biotechnology company focused on genetic diseases.
VIVUS
VIVUS, Inc. is a drug-development company dedicated to the development and commercialization of next-generation therapeutic products
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2024-03-05 | Peak Bio | Peak Bio acquired by Akari Therapeutics | N/A |
Investors List
Samir R Patel
Samir R Patel investment in Post-IPO Equity - Akari Therapeutics
Ray Prudo
Ray Prudo investment in Post-IPO Equity - Akari Therapeutics
Ray Prudo
Ray Prudo investment in Post-IPO Equity - Akari Therapeutics
Ray Prudo
Ray Prudo investment in Post-IPO Equity - Akari Therapeutics
Vivo Capital
Vivo Capital investment in Post-IPO Equity - Akari Therapeutics
Venrock
Venrock investment in Post-IPO Equity - Akari Therapeutics
RA Capital Management
RA Capital Management investment in Post-IPO Equity - Akari Therapeutics
QVT Financial
QVT Financial investment in Post-IPO Equity - Akari Therapeutics
Deerfield
Deerfield investment in Post-IPO Equity - Akari Therapeutics
Foresite Capital
Foresite Capital investment in Post-IPO Equity - Akari Therapeutics
Key Employee Changes
Official Site Inspections
http://www.akaritx.com Semrush global rank: 7.87 M Semrush visits lastest month: 681
- Host name: cloudproxy10158.sucuri.net
- IP address: 192.124.249.158
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Akari Therapeutics"
COMPANY OVERVIEW - Akari Therapeutics
Akari Therapeutics, Plc (NASDAQ: AKTX) is a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akari’s lead asset, …See details»
Akari Therapeutics - Crunchbase Company Profile
Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan …See details»
Akari Therapeutics, Plc | LinkedIn
Akari Therapeutics, Plc (Nasdaq: AKTX) is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akari’s lead asset, investigational nomacopan, is a ...See details»
Akari Therapeutics - Overview, News & Similar companies
Aug 21, 2024 www.akaritx.com. Revenue $16.8 Million. Stock Symbol AKTX. Industry Pharmaceuticals Healthcare . Most Recent Scoops. Aug 22 2024. Earnings. Aug 22 2024. …See details»
A K A R I T H E R A P E U T I C S , P L C - investor.akaritx.com
Incorporation or organization) (IRS. Employer Identification No.) 75/ 76 Wi mp ol e S tre e t L on d on W1G 9RT U n i te d K i n gd om Te l e p h on e + 44 20 8004 0270 (Address and telephone …See details»
Akari Therapeutics Announces the Appointment of Beth-Anne …
NEW YORK and LONDON, Aug. 02, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for …See details»
A k ar i T h e r ap e u ti c s , P L C
(Jurisdiction of incorporation or organization) 75/ 76 Wi mp ol e S tre e t L on d on W1G 9RT U n i te d K i n gd om (Address of principal executive offices) C l i ve R i c h ar d s on C h i e f E xe c …See details»
Relationship: X Executive Officer Director Promoter
Last Name First Name Middle Name Hill James Street Address 1 Street Address 2 c/o Akari Therapeutics Plc The Gridiron Building, One Pancras Squar City State/Province/Country …See details»
Akari Therapeutics Announces Shareholder Approval in …
Nov 8, 2024 Akari’s lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. The Company is conducting …See details»
Morria Biopharmaceuticals - Crunchbase Company Profile
Contact Email [email protected] Phone Number 44 (0)20 3322 1321 Morria Biopharmaceuticals Plc, a biopharmaceutical company, engages in the discovery and development of non …See details»
4 +3 ' * ' & ' . % * %' %& ' - investor.akaritx.com
Author: Morningstar Document Research / Morningstar, Inc. Created Date: 4/7/2017 3:03:34 AMSee details»
AKARI THERAPEUTICS PLC Security Rating - securityscorecard.com
See the quantity and duration of malware infections, along with other factors influence the overall assessment of an organization’s IP Reputation. Endpoint Security Understand the …See details»
Akari Therapeutics Announces Successful Completion of Merger of …
Nov 14, 2024 For more information about Akari, please visit akaritx.com. Cautionary Note Regarding Forward-Looking Statements . This press release includes express or implied …See details»
AKTX Stock Price & Charts | Akari Therapeutics
In depth view into AKTX (Akari Therapeutics) stock including the latest price, news, dividend history, earnings information and financials.See details»
Akari Therapeutics Appoints Experienced Life Sciences …
NEW YORK and BOSTON, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for …See details»
PRIVACY - Akari Therapeutics
Request for the receipt or the transfer to another organization of the personal information that you have provided to Akari; complain to your local data protection authority if your privacy rights …See details»
Akari Therapeutics, Plc (AKTX) - Yahoo Finance Canada
Find the latest Akari Therapeutics, Plc (AKTX) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
May 1, 2024 For more information about Akari, please visit akaritx.com. About Peak Bio, Inc. Peak Bio (OTC: PKBO) is a clinical-stage biopharmaceutical company focused on developing …See details»
Notice of Annual General Meeting of Shareholders (AGM) to be …
Jun 5, 2021 Mr. Byrne is currently Group Chief Executive Officer of Sonic Healthcare UK Group, the United Kingdom’s largest NGO clinical diagnostics organization, a position that he has held …See details»